There is a growing expectation that targeted drug delivery will greatly improve anticancer therapy. To accelerate attaining this goal, we introduced a new synthesis to prepare modular, biodegradable polyester dendritic polymers of various architectures. We showed that a Bow-tie architecture, with PEG on 1 dendron and doxorubicin on the other dendron, was a superior drug carrier in a murine tumor model. We will attach other drugs to the Bow-tie and test the hypothesis that optimal drug release rates are required for therapeutic success. We will also employ recent synthetic advances to devise novel dendritic polymers that: a.) Simultaneously deliver 2 drugs; b.) Have greater payloads and a targeting ligand; c.) Have improved linkages for drug attachment and controlled drug release. Using these novel macromolecules, we will test the following hypotheses related to the factors that contribute to superior anti-cancer therapy of the polymeric drug.
In specific aim 1, using the bow-tie polymers, we will test the hypothesis that a specified combination of polymer-drug uptake in the tumor and drug release rate from the polymer is required to optimize anti-tumor activity. We hypothesize that the optimal release rate will differ for each anticancer agent tested: doxorubicin, cis-platinum, a camptothecin derivative, a fluoropyrimidine and paclitaxel.
In specific aim 2, we will devise synthetic routes for attaching 2 of the above drugs, at defined ratios, to a single polymer. We will use this """"""""double barrel"""""""" polymer to test the hypothesis that the simultaneous delivery to rodent solid tumors of 2 appropriately selected drugs is synergistic compared to the drugs administered together but on different polymers or together as free drugs.
In specific aim 3, we will develop a new synthesis of polyester dendronized polymers of high molecular weight and with various architectures. We will examine the influence of molecular weight/architecture on the pharmacokinetic properties and targeting potential. We use the more promising polymer architectures to test the hypothesis that a high number of drugs per targeting ligand are required for effective ligand-mediated drug targeting. Completion of this research will enable a variety of substantially improved targeted therapies and diagnostic imaging applications that can be successfully applied to treat humans with cancer. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
5R01EB002047-07
Application #
7434459
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Henderson, Lori
Project Start
2002-04-01
Project End
2010-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
7
Fiscal Year
2008
Total Cost
$417,388
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Kierstead, Paul H; Okochi, Hideaki; Venditto, Vincent J et al. (2015) The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release 213:1-9
Kohli, Aditya G; Kierstead, Paul H; Venditto, Vincent J et al. (2014) Designer lipids for drug delivery: from heads to tails. J Control Release 190:274-87
Kieler-Ferguson, Heidi M; Frechet, Jean M J; Szoka Jr, Francis C (2013) Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5:130-8
Klemm, Piper J; Floyd 3rd, William C; Smiles, Danil E et al. (2012) Improving T? and T? magnetic resonance imaging contrast agents through the conjugation of an esteramide dendrimer to high-water-coordination Gd(III) hydroxypyridinone complexes. Contrast Media Mol Imaging 7:95-9
Chen, Bo; van der Poll, Derek G; Jerger, Katherine et al. (2011) Synthesis and properties of star-comb polymers and their doxorubicin conjugates. Bioconjug Chem 22:617-24
Floyd 3rd, William C; Datta, Gopal K; Imamura, Shinichi et al. (2011) Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice. ChemMedChem 6:49-53
Floyd 3rd, William C; Klemm, Piper J; Smiles, Danil E et al. (2011) Conjugation effects of various linkers on Gd(III) MRI contrast agents with dendrimers: optimizing the hydroxypyridinonate (HOPO) ligands with nontoxic, degradable esteramide (EA) dendrimers for high relaxivity. J Am Chem Soc 133:2390-3
van der Poll, Derek G; Kieler-Ferguson, Heidi M; Floyd, William C et al. (2010) Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. Bioconjug Chem 21:764-73
Fox, Megan E; Guillaudeu, Steve; Fréchet, Jean M J et al. (2009) Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. Mol Pharm 6:1562-72
Chen, Bo; Jerger, Katherine; Fréchet, Jean M J et al. (2009) The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly(acrylic acid) comb polymers. J Control Release 140:203-9

Showing the most recent 10 out of 29 publications